Ignite Creation Date:
2024-05-06 @ 1:04 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01722396
Status:
COMPLETED
Last Update Posted:
2013-01-16
First Post:
2012-11-02
Brief Title:
Pharmacogenetics of Vitamin D Supplementation in Tuberculosis
Sponsor:
University of Birmingham
Organization:
University of Birmingham
Study Overview
Official Title:
The Pharmacogenetics of Vitamin D Supplementation in Tuberculosis
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Previous studies of vitamin D supplementation have suggested there may be differences in response between individuals This study is an open label study of vitamin D supplementation in patients with active or latent tuberculosis in which active disease patients take 100000units of vitamin D every 8 weeks during their tuberculosis treatment Genotyping for relevant vitamin D pathway polymorphisms will be carried out and related to clinical and ex vivo markers of vitamin D response Latent patients will only be studied for vitamin D response ex vivo Our hypothesis is that response to vitamin D in both monocytes and T cells will be related to polymorphisms in the DBP gene and that this may relate to clinical response in terms of post supplementation vitamin D level
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None